Journal: bioRxiv
Article Title: Lung-Selective Immune Reprogramming via In Situ Red Blood Cell Hitchhiking Nanoparticles
doi: 10.64898/2026.02.27.708550
Figure Lengend Snippet: a-g, Therapeutic efficacy of i-Bind NPs loaded with diABZI and other control formulations (n=7 biologically independent animals). a, Schematic illustration of the treatment schedule. Created in BioRender. Zhao, Z. (2025) https://BioRender.com/ut0otug . b, Representative bioluminescence images of lung metastasis progression at different time points. c, Lung metastasis progression of individual mouse indicated by bioluminescence intensity. d, Overall lung metastasis progression curve. e, Lung metastasis tumor burden on day 22 indicated by bioluminescence intensity. f, Representative images of lungs following different treatments on day 23. g, Number of surface metastatic nodules on the lungs on day 23. h-p, Changes of the lung immune cell profiles following different treatments on day 23 (n=6 biologically independent animals). h-i, Number of total CD45 + immune cells (h) and various immune cell subtypes (i) in the lungs. j, Number of CD103 + cDC1s and CD11b + cDC2s in the lungs. k, Relative ratio of cDC1s to cDC2s. l, Expression level of DC activation marker CD86 on cDC1s (indicated by Mean fluorescence intensity, MFI). m, Number of CD4 and CD8 T cells in the lungs. n, Relative ratio of CD8 to CD4 T cells in the lungs. o, Relative number of IFN-γ-expressing CD8 T cells of total CD3 T cells in the lungs. p, Relative number of Tregs of total CD3 T cells in the lungs. Data in (e, g-h, j-p) are presented as mean ± SEM. For (e, g-i, j-p) , statistical analysis was conducted by one-way ANOVA followed by Dunnett’s test: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. For ( i ), black, pink, and green asterisks indicate comparisons between the i-Bind diABZI group with saline, PLGA diABZI, and free diABZI groups, respectively.
Article Snippet: STING agonist diABZI (Compound 3) was purchased from Selleck Chemicals LLC (Houston, TX).
Techniques: Drug discovery, Control, Expressing, Activation Assay, Marker, Fluorescence, Saline